- Home
- ICCM vs APLT Comparison
ICCM vs APLT Comparison
Compare ICCM & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICCM | APLT |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.5M | 38.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ICCM | APLT |
|---|---|---|
| Price | $0.68 | $0.22 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $2.50 | $1.25 |
| AVG Volume (30 Days) | 403.0K | ★ 26.6M |
| Earning Date | 11-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,975,000.00 | $1,000,000.00 |
| Revenue This Year | $13.67 | $124.18 |
| Revenue Next Year | $38.55 | $66.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.59 | $0.20 |
| 52 Week High | $1.66 | $1.50 |
Technical Indicators
Market Signals| Indicator | ICCM | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 40.13 | 28.72 |
| Support Level | $0.67 | $0.20 |
| Resistance Level | $0.73 | $0.24 |
| Average True Range (ATR) | 0.04 | 0.03 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 56.00 | 12.38 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.